Cover Image
市場調查報告書

Quantum Genomics SA的產品平台分析

Quantum Genomics SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 327902
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Quantum Genomics SA的產品平台分析 Quantum Genomics SA - Product Pipeline Review - 2015
出版日期: 2015年02月28日 內容資訊: 英文 23 Pages
簡介

Quantum Genomics SA是總公司在法國的生物製藥企業。進行高血壓、心臟衰竭等心血管系統疾病領域的治療藥開發,進行創新的醫藥品開發平台的腦胺肽酶A抑制劑的研究。

本報告提供Quantum Genomics SA 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Quantum Genomics SA 基本資料

  • Quantum Genomics SA 概要
  • 主要資訊
  • 企業資料

Quantum Genomics SA :R&D概要

  • 主要的治療範圍

Quantum Genomics SA :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Quantum Genomics SA :開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Quantum Genomics SA :藥物簡介

  • QGC-001
  • QGC-011
  • QGC-101
  • QGC-006

Quantum Genomics SA :開發平台分析

  • 各給藥途徑
  • 各分子類型

Quantum Genomics SA :最近的開發平台資訊

Quantum Genomics SA :開發休止的計劃

Quantum Genomics SA :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06805CDB

Summary

Global Markets Direct's, 'Quantum Genomics SA - Product Pipeline Review - 2015', provides an overview of the Quantum Genomics SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Quantum Genomics SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Quantum Genomics SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Quantum Genomics SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Quantum Genomics SA's pipeline products

Reasons to buy

  • Evaluate Quantum Genomics SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Quantum Genomics SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Quantum Genomics SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Quantum Genomics SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Quantum Genomics SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Quantum Genomics SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Quantum Genomics SA Snapshot
    • Quantum Genomics SA Overview
    • Key Information
    • Key Facts
  • Quantum Genomics SA - Research and Development Overview
    • Key Therapeutic Areas
  • Quantum Genomics SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Quantum Genomics SA - Pipeline Products Glance
    • Quantum Genomics SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Quantum Genomics SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Quantum Genomics SA - Drug Profiles
    • QGC-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • QGC-011
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • QGC-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • QGC-006
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Quantum Genomics SA - Pipeline Analysis
    • Quantum Genomics SA - Pipeline Products by Route of Administration
    • Quantum Genomics SA - Pipeline Products by Molecule Type
  • Quantum Genomics SA - Recent Pipeline Updates
  • Quantum Genomics SA - Dormant Projects
  • Quantum Genomics SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Quantum Genomics SA, Key Information
  • Quantum Genomics SA, Key Facts
  • Quantum Genomics SA - Pipeline by Indication, 2015
  • Quantum Genomics SA - Pipeline by Stage of Development, 2015
  • Quantum Genomics SA - Monotherapy Products in Pipeline, 2015
  • Quantum Genomics SA - Phase II, 2015
  • Quantum Genomics SA - Preclinical, 2015
  • Quantum Genomics SA - Discovery, 2015
  • Quantum Genomics SA - Pipeline by Route of Administration, 2015
  • Quantum Genomics SA - Pipeline by Molecule Type, 2015
  • Quantum Genomics SA - Recent Pipeline Updates, 2015
  • Quantum Genomics SA - Dormant Developmental Projects,2015

List of Figures

  • Quantum Genomics SA - Pipeline by Top 10 Indication, 2015
  • Quantum Genomics SA - Pipeline by Stage of Development, 2015
  • Quantum Genomics SA - Monotherapy Products in Pipeline, 2015
Back to Top